Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

被引:866
|
作者
McCarthy, Philip L. [1 ]
Owzar, Kouros [5 ,6 ]
Hofmeister, Craig C. [9 ]
Hurd, David D. [7 ]
Hassoun, Hani [3 ]
Richardson, Paul G. [10 ]
Giralt, Sergio [3 ]
Stadtmauer, Edward A. [11 ]
Weisdorf, Daniel J. [12 ]
Vij, Ravi [13 ]
Moreb, Jan S. [14 ]
Callander, Natalie Scott [15 ]
Van Besien, Koen [17 ]
Gentile, Teresa [2 ]
Isola, Luis [4 ]
Maziarz, Richard T. [19 ]
Gabriel, Don A. [8 ]
Bashey, Asad [20 ]
Landau, Heather [3 ]
Martin, Thomas [21 ]
Qazilbash, Muzaffar H. [22 ]
Levitan, Denise [7 ]
McClune, Brian [12 ]
Schlossman, Robert [10 ]
Hars, Vera [6 ]
Postiglione, John [6 ]
Jiang, Chen [6 ]
Bennett, Elizabeth [6 ]
Barry, Susan [6 ]
Bressler, Linda [18 ]
Kelly, Michael [18 ]
Seiler, Michele [18 ]
Rosenbaum, Cara [17 ]
Hari, Parameswaran [16 ]
Pasquini, Marcelo C. [16 ]
Horowitz, Mary M. [16 ]
Shea, Thomas C. [8 ]
Devine, Steven M. [9 ]
Anderson, Kenneth C. [10 ]
Linker, Charles [21 ]
机构
[1] Roswell Pk Canc Inst, BMT Program, Buffalo, NY 14263 USA
[2] SUNY Hlth Sci Ctr, Syracuse, NY 13210 USA
[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[4] Mt Sinai Med Ctr, BMT, New York, NY 10029 USA
[5] Duke Univ, Dept Biostat & Bioinformat, Durham, NC USA
[6] Duke Univ, Canc & Leukemia Grp B CALGB, Ctr Stat, Durham, NC USA
[7] Wake Forest Univ, Winston Salem, NC 27109 USA
[8] Univ N Carolina, Dept Med, Chapel Hill, NC USA
[9] Ohio State Univ, Div Hematol, Ctr Comprehens Canc, Columbus, OH 43210 USA
[10] Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA
[11] Univ Penn, Myeloma Program, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[12] Univ Minnesota, Med Ctr, Dept Hematol & Oncol, Minneapolis, MN 55455 USA
[13] Washington Univ, Div Oncol, Sch Med, St Louis, MO 63130 USA
[14] Univ Florida, Bone Marrow Transplant Program, Gainesville, FL USA
[15] Univ Wisconsin, Dept Hematol, Madison, WI 53706 USA
[16] Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA
[17] Univ Chicago Hosp, Dept Med, Chicago, IL 60637 USA
[18] Univ Chicago, CALGB, Chicago, IL 60637 USA
[19] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[20] BMT Grp Georgia, Atlanta, GA USA
[21] Univ Calif San Francisco, Dept Hematol & Oncol, San Francisco, CA 94143 USA
[22] Univ Texas MD Anderson Canc Ctr, Unit 423, Houston, TX 77030 USA
来源
NEW ENGLAND JOURNAL OF MEDICINE | 2012年 / 366卷 / 19期
关键词
INTERGROUPE FRANCOPHONE; CONSOLIDATION THERAPY; RESPONSE CRITERIA; IMPROVES SURVIVAL; MAINTENANCE; THALIDOMIDE; BORTEZOMIB; DEXAMETHASONE; LEUKEMIA; PREDNISONE;
D O I
10.1056/NEJMoa1114083
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Data are lacking on whether lenalidomide maintenance therapy prolongs the time to disease progression after autologous hematopoietic stem-cell transplantation in patients with multiple myeloma. Methods Between April 2005 and July 2009, we randomly assigned 460 patients who were younger than 71 years of age and had stable disease or a marginal, partial, or complete response 100 days after undergoing stem-cell transplantation to lenalidomide or placebo, which was administered until disease progression. The starting dose of lenalidomide was 10 mg per day (range, 5 to 15). Results The study-drug assignments were unblinded in 2009, when a planned interim analysis showed a significantly longer time to disease progression in the lenalidomide group. At unblinding, 20% of patients who received lenalidomide and 44% of patients who received placebo had progressive disease or had died (P<0.001); of the remaining 128 patients who received placebo and who did not have progressive disease, 86 crossed over to lenalidomide. At a median follow-up of 34 months, 86 of 231 patients who received lenalidomide (37%) and 132 of 229 patients who received placebo (58%) had disease progression or had died. The median time to progression was 46 months in the lenalidomide group and 27 months in the placebo group (P<0.001). A total of 35 patients who received lenalidomide (15%) and 53 patients who received placebo (23%) died (P=0.03). More grade 3 or 4 hematologic adverse events and grade 3 non-hematologic adverse events occurred in patients who received lenalidomide (P<0.001 for both comparisons). Second primary cancers occurred in 18 patients who received lenalidomide (8%) and 6 patients who received placebo (3%). Conclusions Lenalidomide maintenance therapy, initiated at day 100 after hematopoietic stem-cell transplantation, was associated with more toxicity and second cancers but a significantly longer time to disease progression and significantly improved overall survival among patients with myeloma.
引用
收藏
页码:1770 / 1781
页数:12
相关论文
共 50 条
  • [31] Dose Finding Study of Lenalidomide as Maintenance Therapy In Multiple Myeloma After Allogeneic Stem Cell Transplantation
    Wolschke, Christine
    Schonland, Stefan O.
    Hegenbart, Ute
    Stuebig, Thomas
    Heinzelmann, Marion
    Hildebrandt, York
    Lioznov, Michael
    Zander, Axel R.
    Kroeger, Nicolaus
    BLOOD, 2010, 116 (21) : 984 - 984
  • [32] Importance of Achieving Stringent Complete Response After Autologous Stem-Cell Transplantation in Multiple Myeloma
    Kapoor, Prashant
    Kumar, Shaji K.
    Dispenzieri, Angela
    Lacy, Martha Q.
    Buadi, Francis
    Dingli, David
    Russell, Stephen J.
    Hayman, Suzanne R.
    Witzig, Thomas E.
    Lust, John A.
    Leung, Nelson
    Lin, Yi
    Zeldenrust, Steven R.
    McCurdy, Arleigh
    Greipp, Philip R.
    Kyle, Robert A.
    Rajkumar, S. Vincent
    Gertz, Morie A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (36) : 4529 - +
  • [33] Frontline treatment in multiple myeloma patients not eligible for stem-cell transplantation
    Facon, Thierry
    Darre, Stephane
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2007, 20 (04) : 737 - 746
  • [34] Single versus double autologous stem-cell transplantation for multiple myeloma
    Attal, M
    Harousseau, JL
    Facon, T
    Guilhot, F
    Doyen, C
    Fuzibet, JG
    Monconduit, M
    Hulin, C
    Caillot, D
    Bouabdallah, R
    Voillat, L
    Sotto, JJ
    Grosbois, B
    Bataille, R
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (26): : 2495 - 2502
  • [35] PERIPHERAL-BLOOD STEM-CELL TRANSPLANTATION IN MULTIPLE-MYELOMA
    RAJE, N
    POWLES, R
    MEHTA, J
    SINGHAL, S
    MILAN, S
    HORTON, C
    VINER, C
    TRELEAVEN, J
    BLOOD, 1994, 84 (10) : A719 - A719
  • [36] Autologous Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Therapies
    Parrondo, Ricardo D.
    Ailawadhi, Sikander
    Sher, Taimur
    Chanan-Khan, Asher A.
    Roy, Vivek
    JCO ONCOLOGY PRACTICE, 2020, 16 (02) : 56 - +
  • [37] ATLAS: A phase 3 randomized trial of carfilzomib, lenalidomide, and dexamethasone versus lenalidomide alone after stem-cell transplant for multiple myeloma.
    Dytfeld, Dominik
    Wrobel, Tomasz
    Jamroziak, Krzysztof
    Kubicki, Tadeusz
    Robak, Pawel
    Czyz, Jaroslaw
    Tyczynska, Agata
    Druzd-Sitek, Agnieszka
    Giannopoulos, Krzysztof
    Nowicki, Adam
    Lojko-Dankowska, Anna
    Matuszak, Magdalena
    Gil, Lidia
    Pula, Bartosz
    Rybka, Justyna
    Usnarska-Zubkiewicz, Lidia
    Czabak, Olga
    Stefka, Andrew T.
    Derman, Benjamin Avi
    Jakubowiak, Andrzej J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [38] The efficacy and safety of lenalidomide in the treatment of multiple myeloma patients after allo-hematopoietic stem-cell transplantation: a systematic review and meta-analysis
    Zhong, Jiansheng
    Zhang, Xing
    Liu, Minyan
    ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (07) : 7736 - 7746
  • [39] Gastric relapse of plasma-cell myeloma after stem-cell transplantation
    Pollheimer, Verena S.
    Pollheimer, Marion J.
    Eherer, Andreas J.
    Langner, Cord
    GASTROINTESTINAL ENDOSCOPY, 2007, 66 (01) : 179 - 180
  • [40] AUTOLOGOUS BLOOD STEM-CELL TRANSPLANTATION IN MYELOMA
    BELL, AJ
    TRANSFUSION SCIENCE, 1990, 11 (3-4): : 375 - 380